Previous 10 | Next 10 |
The first patient has been dosed in an open-label Phase 1/2 clinical trial evaluating Bicycle Therapeutics' (NASDAQ: BCYC ) BT8009, a Bicycle Toxin Conjugate (BTC) targeting a tumor antigen called nectin-4, in patients with advanced solid tumors. More news on: Bicycle Therapeutics plc,...
- BT8009 is the third program designed to explore the potential of Bicycles® as next-generation tumor-targeting agents - BT8009 targets Nectin-4, a well-validated tumor antigen shown to be overexpressed in several common tumor types Bicycle Therapeutics plc (NASDAQ: BCY...
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that management will participate in the following virtual investor conferences i...
- Two cohorts have been initiated: a squamous non-small cell lung cancer cohort and a solid tumor “basket” cohort; up to two additional cohorts may be added based on preliminary results - Patients will be selected using prespecified tumor membrane H-scores for MT1-MMP ex...
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that the first patient has been dosed in Oxurion’s Phase II study of TH...
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced the appointment of Dominic Smethurst, MA, MBChB, MRCP, MFPM as Chief Medical O...
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that management will participate in a fireside chat at the Canaccord Genuity 40 ...
Bicycle Therapeutics (NASDAQ: BCYC ) : Q2 GAAP EPS of -$0.67 misses by $0.16 . More news on: Bicycle Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more ...
- Progress across pipeline continues with BT1718 Phase IIa and BT8009 Phase I/II trial initiations on-track for this year - Cash was $96.9 million at June 30, 2020, which excludes $17.6 million net proceeds from ATM offering program and a $6.7 million UK R&D tax credit, both receiv...
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced the appointment of Sir Keith Peters FRS as Chairman of the Company’s Scie...
News, Short Squeeze, Breakout and More Instantly...
Bicycle Therapeutics plc Company Name:
BCYC Stock Symbol:
NYSE Market:
Bicycle Therapeutics plc Website:
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ® ) technology, today announced the acceptance of four abstracts for poster presentation at the European So...
2024-06-10 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Emerging clinical pharmacokinetic and safety profiles of Bicycle Toxin Conjugates ® demonstrate differentiation compared to antibody drug conjugates Trial-in-progress poster outlines registrational Phase 2/3 Duravelo-2 trial of BT8009, a Nectin-4 targeted Bicycle Toxin Conjugate,...